Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer

Overview of attention for article published in Clinical Cancer Research, May 2024

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (91st percentile)
High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

blogs: 1 blog

twitter: 27 X users

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 5 Mendeley

Summary Blogs X Dimensions citations

So far, Altmetric has seen 1 blog post.

Antibody Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Cancer Therapy Strategy in Breast Cancer Patients

Stemcell science news, 06 May 2024

Scientists assessed proof-of-mechanism and clinical feasibility for Sacituzumab govitecan (SG) and talazoparib employing an…

This page shows the most recent blog posts that mention this research output.

Click here to find out how to access more activity.